“… Sr. No. | Vaccines Category | Vaccine Candidates Under Clinical Trials | Reference |
1 | HA protein-based vaccine | - HA Rosettes, HA nanoparticles, VLP + Matrix-MTM adjuvant HA stem or head-stem chimeraFlu Blok (recombinant) Monoglycosylated HA- a universal flu vaccine candidate, with conserved domain
| [32] , [35] , [91] |
2 | Epitope-peptides based vaccine (NA or HA based vaccines) | - HA, NP, M1 peptides FLU-V MVA-vectored NP + M1 vaccine
| [51] , [52] , [53] , [54] , [55] , [56] , [97] , [98] , [53] , [156] |
3 | Live attenuated virus vaccine | - CodaVaxFluMist (AstraZeneca) M2SRFluenz Tetra (licensed)M2-deficient single replication virus (targeting B cells) Approved vaccines A/Len/134/17/57, A/Len/134/47/57, B/USSR/60/69, A/Ann Arbor/6/60, B/Ann Arbor/1/66
| [35] , [35] , [109] , [110] , [111] , [157] , [158] |
4 | Nucleic acid-based vaccine | - Vaccines candidates belonging to DNA and Mrna targeting HA Nabs DNA based- mucosal influenza vaccines – FluMist
| [17] , [109] , [122] , [123] , [124] , [159] , [160] |
5 | Virus like particles-based vaccines (recombinant technology) | - M2e5x VLP vaccinesM2 VLP-supplemented inactiv...
|
…”